Author: Sarah Baker

Series: Advanced Biostatistics for MedTech: Bridging Clinical Evaluation and Engineering The Statistical Advantage of Iterative Device Development Devices are iterative, physical, and engineerable. By the time a device reaches a pivotal clinical investigation, it has undergone extensive Verification and Validation (V&V) bench testing, biocompatibility assessments, and often animal studies. The physics of the device (such as its tensile strength, fatigue…

Series: Advanced Biostatistics for MedTech: Bridging Clinical Evaluation and Engineering The Regulatory Rejection of "Industry Standard" Sample Sizes One of the most frequently cited Major Non-Conformities in Notified Body audit reports under the EU Medical Device Regulation (MDR 2017/745) and IVDR 2017/746 is the inadequate statistical justification of sample sizes. During design control reviews and Clinical Evaluation Report (CER) appraisals,…

Series: Advanced Biostatistics for MedTech: Bridging Clinical Evaluation and Engineering The Regulatory Trap of "Substantial Equivalence" The regulatory pathways for medical devices in the United States and Europe rely heavily on the concept of equivalence. Under the US FDA 510(k) framework, a manufacturer must demonstrate that a new device is "substantially equivalent" to a legally marketed predicate. In Europe, the…

Series: Advanced Biostatistics for MedTech: Bridging Clinical Evaluation and Engineering The Regulatory Demand for Analytical Rigour in IVDs The transition from the In Vitro Diagnostic Directive (IVDD 98/79/EC) to the In Vitro Diagnostic Regulation (IVDR 2017/746) has fundamentally altered the analytical performance expectations for medical devices in the EU/EEA (and Northern Ireland under the Windsor Framework), with Great Britain accepting…

Series: Advanced Biostatistics for MedTech: Bridging Clinical Evaluation and Engineering The Pharma Paradigm vs. The MedTech Reality Graduate-level biostatistics curricula are largely rooted in the pharmaceutical paradigm. Academic training typically focuses on ICH E9 statistical principles, large-scale randomised controlled trials (RCTs), adaptive dose-finding, and survival analysis using Cox proportional hazards models. The statistical machinery is built to prove the efficacy…

Medical device clinical investigations, as formally regulated under FDA Investigational Device Exemption (IDE) rules or EU MDR/ISO 14155 guidelines, increasingly incorporate adaptive methodologies to improve efficiency and patient outcomes. Two primary approaches have emerged: Multi-Arm Multi-Stage (MAMS) designs, which evaluate arms at predefined milestones to drop inferior treatments or stop early for efficacy, typically maintaining a fixed allocation ratio among…